{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"8.34"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"84.44"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"80.95"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"78.29"},{"comment":"Not estimable because insufficient number of participants have events (progressed or relapsed).","groupId":"OG005","lowerLimit":"52.11","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"Duration of response was measured from the first documentation of objective response (OR) to the first documented non-response of SD, PD, or relapse and was only evaluated in participants who had achieved an OR (CR or PR). Duration of OR was summarized using Kaplan-Meier estimates (median time, 95% CI for median time).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV 5 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG000","title":"5 mcg/kg"},{"description":"Participants received IV 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG001","title":"10 mcg/kg"},{"description":"Participants received IV 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG002","title":"20 mcg/kg"},{"description":"Participants received IV 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG003","title":"30 mcg/kg"},{"description":"Participants received IV 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG004","title":"40 mcg/kg"},{"description":"Participants received IV 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG005","title":"50 mcg/kg"}],"paramType":"MEDIAN","populationDescription":"Safety population included all participants who received any treatment of moxetumomab pasudotox. Here, the \"Overall Number of Participants Analyzed\" denotes the number of participants who had achieved an OR (CR or PR) and had the first documented non-response of SD, PD, or relapse.","reportingStatus":"POSTED","timeFrame":"From Baseline (predose of Cycle 1 Day 1) through end of study (until CR, PD, initiation of alternative therapy, unacceptable toxicity, development of neutralizing antibodies, or other study discontinuation reasons) (approximately 8 years)","title":"Duration of Objective Response","type":"PRIMARY","unitOfMeasure":"months"}